Table 3. Estimated short- and long-term cumulative changes in CRC incidence and CRC mortality attributable to screening, diagnosis, and treatment decreases in 2020 and 2021.

All results are vs “no pandemic” scenario (see Table 1). Numbers in brackets are relative changes. Includes short-term decreases to incidence due to reductions in diagnoses, and long-term increases due to CRC which were not removed at screening at a precancerous stage.

			2020–2021	2020–2025	2020–2030	2020–2050
Australia	Changes in CRC incidence vs no pandemic		-1,672 (-4.7%)	-630 (-.6%)	234 (.1%)	1,065 (.1%)
	Changes in CRC mortality vs no pandemic	Screening-related	-9	40	123	396
		Diagnoses/treatment related	100	764	1,063	1,068
		Total (no mitigation)	91 (1.1%)	805 (3.1%)	1,186 (2.4%)	1,464 (0.9%)
		Total (5% mitigation)	91 (1.1%)	631 (2.4%)	842 (1.7%)	1,114 (0.7%)
Canada	Changes in CRC incidence vs no pandemic		-1,398 (-3.1%)	-195 (-.2%)	255 (.1%)	443 (.%)
	Changes in CRC mortality vs no pandemic	Screening-related	-16	194	525	805
		Diagnoses/treatment related	334	1,079	1,296	1,070
		Total (no mitigation)	318 (2.0%)	1,272 (2.6%)	1,820 (1.9%)	1,875 (.6%)
		Total (5% mitigation)	306 (1.9%)	629 (1.3%)	1,031 (1.1%)	1,053 (.3%)